Dr. Alberto Lleó is the director of the Memory Unit of the Neurology Department at Hospital de la Santa Creu i Sant Pau.
After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona and continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.
In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.
Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.
- C9orf72, AAO and ancestry help discriminating behavioural from language variants in FTLD cohorts. Costa, B, Manzoni, C, Bernal-Quiros, M et al. Neurology 2020PMID:32943482
- Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. Illán-Gala, I, Montal, V, Pegueroles, J et al. Neurology 2020PMID:32913016
- Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. Frederiksen, KS, Nielsen, TR, Appollonio, I et al. Int J Geriatr Psychiatry 2020PMID:32896040
- Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Shi, L, Winchester, LM, Liu, BY et al. J. Alzheimers Dis. 2020PMID:32831200
- Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. Belbin, O, Xiao, MF, Xu, D et al. Mol Neurodegener 2020PMID:32807227
- Evaluation of biochemical and hematological parameters in adults with Down syndrome. de Gonzalo-Calvo, D, Barroeta, I, Nan, MN et al. Sci Rep 2020PMID:32792619
- Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. Pegueroles, J, Pané, A, Vilaplana, E et al. Alzheimers Dement (Amst) 2020PMID:32743041
- Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Dols-Icardo, O, Montal, V, Sirisi, S et al. Neurol Neuroimmunol Neuroinflamm 2020PMID:32669313
- Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia. Sampedro, F, Stantonyonge, N, Martínez-Horta, S et al. BMJ Open Diabetes Res Care 2020PMID:32636221
- Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests. Benejam, B, Videla, L, Vilaplana, E et al. Alzheimers Dement (Amst) 2020PMID:32613076
- Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Fortea, J, Vilaplana, E, Carmona-Iragui, M et al. Lancet 2020PMID:32593336
- Active bilingualism delays the onset of mild cognitive impairment. Calabria, M, Hernández, M, Cattaneo, G et al. Neuropsychologia 2020PMID:32540266
- Annexin A5 prevents amyloid-β-induced toxicity in choroid plexus: implication for Alzheimer's disease. Bartolome, F, Krzyzanowska, A, de la Cueva, M et al. Sci Rep 2020PMID:32523019
- APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Konijnenberg, E, Tijms, BM, Gobom, J et al. Alzheimers Res Ther 2020PMID:32460813
- Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. Lidón, L, Urrea, L, Llorens, F et al. Cells 2020PMID:32438605